Manufactures and sells specialty chemicals and pharmaceutical products from GMP-certified facilities at Palghar and Hyderabad. The product range covers pharmaceuticals, active pharmaceutical ingredients (APIs), drugs, chemicals, and healthcare products. Growth has come through acquisitions, including Ratna Lifesciences and a 51% stake in Ishwari Healthcare, and through export expansion, supported by a wholly-owned US subsidiary called Sudarshan Industries Inc. incorporated in Delaware. FY26 revenue was ₹703.0565 crore (up from ₹505 crore in FY25), with net profit of ₹23.3717 crore and an EBITDA margin of 8.5382%. Export turnover for FY25-26 was ₹21.85 crore, with a stated minimum target of ₹100 crore for FY26-27. On the cost side, materials accounted for 5.6% of revenue, employees 1.1%, other operating expenses 3.5%, depreciation 0.5%, and capex 9.8%. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Specialty chemicals, Pharmaceuticals and APIs, Exports / overseas sales. Small-cap, asset-intensive specialty chemicals and pharmaceutical manufacturer with growing export operations.
| ₹ crore · consolidated | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | 461 | 464 | 505 | 703 |
| EBITDA (ex other income) | — | — | — | 51 |
| margin % | — | — | — | 7.3 |
| Owners' profit | — | — | — | 23 |
| EPS, as reported (₹) | 5.48 | 4.76 | 0.66 | 0.97 |
| ROE % · ROCE % | — · 13.1 | — · 19.8 | — · 26.2 | 15.0 · 30.3 |
| Debt / equity (x) | — | — | — | 1.81 |
| Cash from operations | (24) | (73) | (26) | (2) |
| Capex | — | — | (1) | (69) |
| ₹ crore | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 232 | 232 | 228 | 277 | 145 | 169 | 168 | 389 |
| Profit before tax | 7 | 9 | 8 | 14 | 5 | 4 | 5 | 21 |
| Net profit | — | — | — | — | 4 | 4 | 4 | 16 |
| EPS (₹) | 2.02 | 2.74 | 2.46 | 0.41 | 0.16 | 0.16 | 0.18 | 0.65 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| PIDILITE INDUSTRIES LTD | 1,59,479 | 60.2 | 14.43 | 42.3 | 22.4 | 28.0 | 14.9 | 28.6 |
| SRF LTD | 73,583 | 34.0 | 5.24 | 22.7 | 13.1 | 13.1 | 13.4 | 25.2 |
| GUJARAT FLUOROCHEM LTD | 52,514 | 85.7 | 6.64 | 41.5 | 7.3 | 8.7 | 13.5 | 27.7 |
| NAVIN FLUORINE INT. LTD | 43,836 | 55.4 | 11.03 | 39.5 | 16.7 | 16.4 | 23.0 | 37.5 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 9 Sept 2026 · Promoter Group Entities Create Pledge on Sudarshan Pharma Shares | ownership changes | high | — | — |
| 9 Sept 2026 · Promoter Hemal Mehta's pledge of 20 lakh shares released | ownership changes | high | — | — |
| 5 Sept 2026 · Sudarshan Pharma to acquire 9.5% stake in US biotech MedTherapy | strategic transactions | high | — | — |
| 1 Sept 2026 · Sudarshan Pharma 18th AGM notice published in newspapers | compliance | minimal | — | — |
| 29 Aug 2026 · Annual Report FY26: revenue up 33 percent, PAT up 57 percent | compliance | low | — | — |
| 29 Aug 2026 · Sudarshan Pharma FY26 Annual Report: Revenue up 33%, PAT at Rs 21.98 Cr | compliance | low | — | — |
| 29 Aug 2026 · 18th AGM Notice - 22 September 2026 via video conferencing | board shareholder meetings | low | — | — |
| 26 Aug 2026 · Promoters disclose pledge creation on shares under SAST Reg 31(2) | ownership changes | high | — | — |
| 22 Aug 2026 · Sudarshan Pharma promoters Hemal and Sachin Mehta create pledge on shares | ownership changes | high | — | — |
| 19 Aug 2026 · FCCB conversion - 48.11 lakh shares allotted at Rs 30.19 each | fund raising | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| AETHER INDUSTRIES LIMITED |
| 22,229 |
| 94.3 |
| 9.05 |
| 60.4 |
| 8.9 |
| 11.4 |
| — |
| 33.8 |
| DEEPAK NITRITE LTD | 21,769 | 27.8 | 3.71 | 22.4 | 9.4 | 10.2 | 12.6 | 21.5 |
| ATUL LTD | 18,401 | 23.1 | 2.92 | 14.9 | 10.9 | 13.3 | 10.9 | 23.1 |
| AARTI INDUSTRIES LTD | 17,846 | 33.6 | 3.00 | 18.8 | 7.0 | 4.4 | 13.0 | 16.2 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 33.9 | 23.4 | 70 of 103 | 32% |
| P/B | 6.0 | 2.9 | 81 of 99 | 18% |
| ROCE | 16.4 | 10.3 | 28 of 108 | 75% |
| ROE | 14.9 | 8.1 | 19 of 101 | 82% |
| Debt / Equity | 1.8 | 0.2 | 97 of 101 | 4% |
| EBITDA margin | 9.4 | 15.5 | 76 of 99 | 24% |
| Revenue growth | 40.3 | 24.4 | 22 of 94 | 77% |
| Market cap | 939 | 732 | 49 of 107 | 55% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
